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Recent clinical trials revealed the impressive efﬁcacy of immunological checkpoint blockade in different types of metastatic
cancers. Such data underscore that immunotherapy is one of the most promising strategies for cancer treatment. In add-
ition, preclinical studies provide evidence that some cytotoxic drugs have the ability to stimulate the immune system,
resulting in anti-tumor immune responses that contribute to clinical efﬁcacy of these agents. These observations raise the
hypothesis that the next step for cancer treatment is the combination of cytotoxic agents and immunotherapies. The
present review aims to summarize the immune-mediated effects of chemotherapeutic agents and their clinical relevance,
the biological and clinical features of immune checkpoint blockers and ﬁnally, the preclinical and clinical rationale for novel
therapeutic strategies combining anticancer agents and immune checkpoint blockers.
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introduction
The involvement of the immune system in tumor control is now
accepted. The ability of innate and adaptive immune cells to
detect and eliminate tumor cells was termed ‘cancer immuno-
surveillance’. However, subsequent studies have shown that
immune cells could also facilitate cancer progression by promot-
ing the growth of tumor clones resistant to anticancer immun-
ity. The term ‘cancer immunoediting’ encapsulates the dual
activity of the immune system on tumors [1]. The positive effect
of the immune system on the control of tumor growth is under-
lined by the observation that HIV infection or immunosuppres-
sive states induced by genetic deﬁciency or immunosuppression
increase the frequency of solid cancers and hematological malig-
nancies in mice and humans [2–5]. Recent data show that
growing tumors are frequently inﬁltrated by immune cells,
notably CD8 T cells and these cells probably contribute to the
control of tumor growth in humans because their presence is
associated with better outcomes [6–8]. This anti-tumor immune
response can be manipulated to enhance tumor immune attack,
leading to clinical beneﬁts for cancer patients. Challenging the
presiding view that chemotherapeutic agents were immunosup-
pressive [9–14], we and others have shown that some che-
motherapeutic agents could elicit an immunogenic form of
tumor cell death that enhances anticancer immune responses
and contributes to the clinical efﬁcacy of these chemotherapies
[15–18]. Although the demonstration of immunogenic cell
death (ICD) relies on mouse models of intratumor injection of
chemotherapy or only one systemic injection of chemotherapy
which do not mimic the clinical setting of repetitive systemic
injections of high doses of chemotherapy, the ﬁndings that
patients with genetic deﬁciencies in molecules involved in the
detection of ICD have poorer prognosis under chemotherapeu-
tic treatment underscore the clinical relevance of this concept
[15–17]. Recently, the use of monoclonal antibodies (mAbs)
blocking key inhibitory receptors of T cells such as cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) and programmed
cell death 1 (PD-1) has led to robust anti-tumor immune responses
and has yielded clinical beneﬁts across multiple tumor types
[19]. In addition, impressive clinical responses were observed
upon adoptive transfer of tumor-speciﬁc autologous T cells
using the generation of T cells that expressed cloned T-cell
receptors (TCRs) or chimeric antigen receptors (CAR) [20].
However, despite these recent successes, many patients are not
cured. Emerging evidence suggest that combination strategies
may be important to achieve deeper tumor responses. Although
combination of immune therapy with some conventional cyto-
toxic chemotherapies can be envisioned, the important question
of how to integrate these novel immunotherapy treatments with
the current clinical strategy still remains. In this review, we will
summarize our knowledge on the immune-mediated effects of
chemotherapies and on the mechanisms of action of novel im-
munotherapies and propose a rationale for the design of syner-
gistic anticancer combinations.
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the emergence of novel
immunotherapeutic strategies
against cancer
dendritic cells
Owing to their strong ability to initiate and control T-cell
responses, dendritic cells (DCs) have long been regarded as at-
tractive candidates for the design of immunotherapy strategies
[21]. Initially, DC cancer vaccines consisted of ex vivo generated
DCs that were loaded with tumor antigens. Although this vaccin-
ation strategy has successfully elicited anticancer immune
responses in cancer patients, no or very few clinical beneﬁts were
noted (reviewed in [22]). This was, for instance, illustrated by the
results of a phase III randomized clinical trial comparing the clin-
ical efﬁcacy of DC therapy to dacarbazine in metastatic melanoma
patients. The objective response rate for DC therapy was 3.8%,
explaining the early discontinuation of the study because of lack
of efﬁcacy [23]. Proposed reasons explaining the lack of efﬁcacy of
DC vaccines include the use of inappropriate DC maturation
cocktail, thus compromising the ability of DC to induce antican-
cer responses. To circumvent these issues, different strategies are
being implemented. Cytokine combinations to favor DC matur-
ation and antigen presentation properties to design more effective
DC-based immunization strategies are being tested (reviewed in
[22, 24]). A recent study demonstrated that the ability of a DC
vaccine to increase, without any associated side effects, the
breadth and diversity of melanoma neoantigen-speciﬁc T cells
further enhances the potential of this approach [25].
adoptive T-cell therapy
Adoptive T-cell therapy for cancer aims to eliminate cancer cells
upon administration of T cells into tumor-bearing hosts. In 1955,
Mitchison [26] initially demonstrated the feasibility of this ap-
proach in mice. In 1966, Southam et al. studied the anticancer
activity of leucocytes from tumor-bearing patients against their re-
spective tumor and raised the hypothesis that lymphocytes from
cancer patients have a speciﬁc inhibitory effect against cancer cells.
This provided impetus to exploit T cells from cancer patients to
design effective adoptive transfer strategies. Subsequent studies
focused on the isolation, expansion and reinfusion of tumor-
inﬁltrating lymphocytes (TILs) into cancer patients. The studies
pioneered by Rosenberg and colleagues relied on the culture of
tumor-derived lymphocytes in the presence of high doses of IL-2
that were then transferred into tumor-bearing patients. Although
encouraging results were noted, side effects impeded the large clin-
ical implementation of this strategy. The safety and efﬁcacy of TIL
therapy was improved by implementing preconditioning regimens
driving lymphodepletion. The use of a preconditioning regimen
relying on cyclophosphamide and ﬂudarabine was shown to
eliminate the endogenous lymphocyte repertoire and favor
growth and long-lasting persistence of the transferred TILs. This
has led to improved responses rate up to 40% [27]. Research in
T-cell biology has also improved TIL culture conditions, leading
to shorter TIL expansion phase, thereby reducing the time from
TIL collection to their reinfusion into cancer patients.
An alternative strategy to target tumor cells using T cells is
the engineering of CAR T cells, which are endowed with a spe-
ciﬁc ability to recognize and kill cancer cells. CARs contain a
fusion protein of light and heavy chains from an antibody,
linked to the signaling machinery of the TCR. Such structure
enables T-cell activation upon CAR recognition of its target. As
CARs are not Major Histocompatibility complex (MHC)-
restricted, they are insensitive to tumor-driven immunosuppres-
sion mediated through downregulation of MHC molecules.
Another advantage of CAR T cells is the possibility of transdu-
cing genes that will enhance further T-cell functions upon acti-
vation or chemokine receptors that will favor T-cell homing.
Although the initial trials in ovarian cancer and renal cell
carcinoma using CAR T cells were disappointing because of tox-
icity and limited T-cell persistence in the tumor microenviron-
ment [28, 29], the use of second-generation CAR T cells in
leukemic patients has resulted in remarkable anticancer effects
[30, 31]. The success of CAR T-cell therapy in these diseases
was associated with a high level of CAR T-cell proliferation fol-
lowing infusion into patients. The feasibility of this approach
was further established in 30 patients suffering from relapsed or
refractory acute lymphoblastic leukemia. CAR T-cell therapy
targeting CD19 led to complete remission in 27 patients and
sustained remission was achieved with a 6-month overall sur-
vival rate of 78% [32]. This notable efﬁcacy has led to the United
States Food and Drug Administration to designate the anti-
CD19 CAR T-cell therapy as a ‘breakthrough therapy’.
cytokines
The efﬁcacy of IL-2 as an anticancer agent has been investigated
in multiple cancer types. It has been shown that high doses of
IL-2 could be effective in eliciting anticancer responses in renal
cell carcinoma and melanoma. Nevertheless, the overall re-
sponse rates were low and the associated toxicities were severe
(reviewed in [22]). IL-2 was further shown to drive the expan-
sion of regulatory T cells which in turn suppress anticancer
immune responses. This has prompted the test of additional
cytokines for their anticancer potential upon in vivo administra-
tion. IL-15 was later identiﬁed as an interesting candidate mol-
ecule. The anticancer effects of IL-15 have been demonstrated in
several preclinical tumor models. The underlying mechanisms
have been subsequently identiﬁed. IL-15 has been shown to
enhance NK cell effector functions. In addition, IL-15 was shown
to support the proliferation and effector functions of CD8 T cells
in the presence of regulatory T cells, suggesting that IL-15 could
preserve the persistence and anticancer functions of T cells in
the tumor microenvironment [33]. The ability of IL-15 to acti-
vate T-cell functions was further exploited in the context of T-
cell therapy. Culture of TILs with IL-15 was indeed shown to
improve the quality of CD8 T cells for adoptive therapy [34].
CAR T cells expressing the IL-15 gene featured greater expan-
sion in vitro and reduced the cell death rate over control CAR T
cells. Upon adoptive transfer in mice, IL-15 expressing CARs
showed enhanced anticancer effects in vivo [35]. The clinical im-
plementation of IL-15 began in 2009. The safety and efﬁcacy of
IL-15 is currently being tested in patients with lymphoma,
melanoma, or renal cell carcinoma ([36] and NCT01572493,
NCT01385423).
In addition to IL-15, IL-21 is also an immunomodulatory
cytokine that is currently being tested for its anticancer activity
in humans. Preclinical studies using IL-21-overexpressing
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tumors revealed that IL-21 prevented B16 melanoma and
MCA205 carcinoma growth and increased mouse survival [37].
In addition, administration of IL-21 was found to control CD8
T-cell expansion and effector functions and to synergize with
IL-15, leading to the rejection of large melanoma tumors in
mice [38]. The ability of IL-21 to enhance T-cell functionality
was shown in the context of adoptive transfer. CD8 T cells cul-
tured with IL-21 enhanced their anticancer activity, leading to
rejection of large tumors upon transfer [39]. Similarly, IL-21
enhances CAR T-cell anticancer functions for effective im-
munotherapy against B-cell malignancies [40]. We have also re-
cently reported that naïve CD4 T cells differentiated into
effector Th9 cells in the presence of TGF-β, IL-4 and IL-1β,
secreted high levels of IL-21 and mediated IL-21-dependent
anticancer effects against melanoma tumors upon adoptive
transfer [41]. IL-21 mediated its anticancer activity through acti-
vation of NK and CD8 T cells which in turn controlled tumor
progression through IFNγ. The clinical efﬁcacy of IL-21 was
investigated in phase I and II trials involving melanoma, renal
cell carcinoma and metastatic colorectal cancer patients. In the
phase II melanoma trial including 40 patients, the overall re-
sponse rate to IL-21 was 22.5%, with 9 patients exhibiting
partial responses and with 16 who had stable disease [42].
checkpoint inhibitors
A balance between co-stimulatory and inhibitory signals regulates
the amplitude and the quality of T-cell responses driven by TCR
signaling. T cells require CD28-mediated co-stimulation (also
known as signal 2) for the full acquisition of effector functions.
However, excessive T-cell activation can result in the loss of self-
tolerance, underscoring the importance of immune inhibitory
pathways, or immune checkpoints, that regulate T-cell activity.
The immunosuppressive tumor microenvironment directly affects
the expression of immune checkpoint proteins, thereby favoring
resistance to anti-tumor immune response. T cells are essential
effectors for cancer immune surveillance, and inhibition of T-cell-
dependent anti-tumor response can promote tumor progression
[43]. Engagement of the CD28 homologue receptor cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) on T cells by co-stimu-
latory molecules negatively regulates T-cell activation [44]. Leach
et al. [45] have exploited this modulation of T-cell function thera-
peutically. They showed that administration of neutralizing CTLA-
4 antibody into tumor-bearing mice resulted in tumor rejection
[45]. In addition, mice that had rejected their tumors following
anti-CTLA-4 treatment were protected against subsequent tumor
rechallenge, indicating the establishment of immunological memory
[45]. Additional mouse and human studies have validated these
results and shown that CTLA-4 blockade triggers anticancer
immune responses. Importantly, inhibition of CTLA-4 signaling
not only enhances effector T-cell functions, but it also renders
effector T cells insensitive to regulatory T-cell-driven suppres-
sion. Infusion of anti-CTLA-4 antibodies after vaccination with
irradiated, autologous tumor cells secreting GM-CSF (GVAX)-
induced anti-tumor immunity but no toxicity in metastatic mel-
anoma patients [46]. The clinical efﬁcacy of anti-CTLA-4
therapy was further conﬁrmed in a phase III clinical trial where ipi-
limumab, a human mAb against CTLA-4, was shown to enhance
the overall survival of metastatic melanoma patients [47]. The
demonstrated anticancer activity of ipilimumab (Yervoy) led to its
approval by the FDA for the treatment of metastatic melanoma.
Other key inhibitory checkpoints that are relevant in cancer
immunotherapy include PD-1 and Tim-3. Expression of the PD-
1 receptor is induced in T cells upon activation [48]. Tumor cells
can drive T-cell dysfunction because of their expression of PD-1
receptor ligands, PD-L1 and PD-L2 [49–52]. Iwai et al. [52] have
shown that transgenic expression of PD-L1 in mastocytoma
tumor cells prevented their elimination by CTL and enhanced
their invasiveness in vivo. Thus, cancer tissues limit the host
immune response through PD-1 ligands and their ligation to PD-
1 on antigen-speciﬁc CD8 T cells, a phenomenon termed adap-
tive immune resistance. The molecular bases accounting for
adaptive immune resistance remain elusive. However, it has been
suggested that the therapeutic efﬁcacy of PD-1 blockade is due to
the restoration of CD8 T-cell effector function in the tumor
microenvironment [53]. Preclinical models have demonstrated
that blockade of PD-L1/PD-1 interactions could reinforce antic-
ancer immune responses and promote tumor control [51, 52]. In
2014, pembrolizumab and nivolumab, two anti-PD-1 antibodies,
were approved by the FDA for the treatment of advanced melan-
oma patients (Table 1). Tim-3 is another T-cell inhibitory recep-
tor that was initially identiﬁed on fully differentiated Th1 cells.
The Tim-3 ligand, galectin-9, induces T-cell death [64]. In the
tumor microenvironment, dysfunctional CD8 T cells could be
identiﬁed by the co-expression of Tim-3 and PD-1. Importantly,
the concomitant administration of neutralizing Tim-3 and PD-1
antibodies showed synergistic effects in preventing tumor out-
growth [65]. As Tim-3 and PD-1 expression are associated with
tumor antigen-speciﬁc CD8+ T-cell dysfunction in melanoma
patients and prevent the expansion of tumor antigen-speciﬁc
Table 1. Published studies having investigated the effect of combination therapies with checkpoint inhibitors
Therapeutic antibody Clinical phase Treatment of Combinatorial treatment given References
Ipilimumab (anti-CTLA-4) I Melanoma Vemurafenib [54]
Ipilimumab (anti-CTLA-4) I Melanoma Nivolumab [55]
Ipilimumab (anti-CTLA-4) III Melanoma Dacarbazine [56, 57]
Ipilimumab (anti-CTLA-4) Ib Pancreatic cancer GM-CSF-secreting vaccine [58]
Ipilimumab (anti-CTLA-4) I/II Prostate cancer GM-CSF-secreting allogeneic vaccine [59]
Ipilimumab (anti-CTLA-4) I/II Prostate cancer GM-CSF [60]
Ipilimumab (anti-CTLA-4) II Small cell lung cancer Paclitaxel and carboplatin [61]
Tremelimumab (anti-CTLA-4) I Melanoma TLR9 agonist PF-3512676 [62]
Nivolumab (anti-PD-1) I Melanoma Peptide vaccine [63]
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CD8 T cells induced by vaccination [66, 67], evaluating the clinic-
al efﬁcacy of anti-Tim-3 antibodies in a clinical setting will be of
high interest. Other therapies targeting immune checkpoints are
currently in development such as agonist antibodies targeting
molecules which activate T cells such as CD137 (BMS-663513)
[68], OX40 (MEDI6383) NCT02221960, CD40 (CP870,893) [69]
or GITR (TRAX518) NCT01239134 as well as drugs favoring DC
activation such as LAG3-Fusion protein (IMP321) [70].
One of the challenging problems with the use of checkpoint
inhibitors is the management of autoimmune side effects called
immune-related adverse events (irAEs) (for detailed review see
[71, 72]. Mild to severe irAEs are observed with ipilimumab in
about 60% of patients and in about 15% with anti-PD-1 drugs.
irAEs include dermatologic, gastrointestinal, hepatic, endocrine,
and other less common inﬂammatory events. IrAEs are believed
to arise from general immunologic enhancement, and tempor-
ary immunosuppression with corticosteroids, tumor necrosis
factor-alpha antagonists, mycophenolate mofetil or other agents
can be an effective treatment in most cases. Interestingly, an as-
sociation between irAEs and clinical outcome was observed for
anti-CTLA-4 therapy [73]. The recent approval of anti-CTLA-4
and anti-PD1 mAbs in the clinic opens a new ﬁeld in cancer im-
munotherapy. The discovery that anti-PD-1 mAb treatment
could be effective in many types of cancers like melanoma, renal
carcinoma, lung cancer, bladder cancer gastric cancer under-
scores the possible development of immune checkpoint inhibi-
tors in many clinical contexts of solid tumors.
In addition to antibodies targeting checkpoint inhibitors, bis-
peciﬁc antibodies are being developed. These antibodies are artiﬁ-
cial proteins that are composed of fragments of two different
mAbs and consequently bind to two different types of antigens.
This approach is used for cancer immunotherapy, where these
proteins simultaneously bind to cytotoxic T cells using CD3
and a tumor cell target. Two drugs are currently available.
Catumaxomab consists of one heavy chain and one light chain
of an anti-EpCAM antibody and one heavy chain and one light
chain of an anti-CD3 antibody as a consequence of which the chi-
meric protein can bind both EpCAM and CD3. In addition, the
Fc-region can bind to an Fc receptor on accessory cells like other
antibodies, which has led to calling the drug a trifunctional anti-
body. This structure allows both T cell and macrophage or DC ac-
tivation to favor adaptive immune response and tumor cell lysis
by immune effectors. This drug could be used to treat patients
with ascites with EpCam+ tumor cells. Blinatumomab is a bi-
speciﬁc T-cell engager that combines two binding sites: a CD3 site
for T cells and a CD19 site to target B cells. The drug works by
linking these two cell types and activating the T cell to exert cyto-
toxic activity on the target cells. Blinatumomab could be used to
target malignant B-cell lymphoma/leukemia and make blinatu-
momab a potential therapeutic option for pediatric and adult
B-cell lymphoma or acute B-cell lymphoblastic leukemia.
rationale to combine conventional
cancer treatments with immunotherapy
combining radiotherapy with immunotherapy
Accumulating data identifying molecular changes in the tumor
microenvironment induced by tumor irradiation have recently
contributed to better understand the contribution of the
immune system in the response of the irradiated tumor [74–76]
(and reviewed in [77] and [78]). Tumor irradiation can induce
the priming of immune response after induction of ICD [15, 79,
80], which could explain the observation of regression of unirra-
diated distant tumor sites (the so-called abscopal effect) [81, 82].
In addition, irradiation of tumor cells contributes to the effector
phase by inducing expression of numerous molecules (MHC I,
NKG2D ligands, death receptors, adhesion molecules) able to
activate effector immune cells [83–87]. Thus, combining radi-
ation with immunotherapy appears to provide an optimal thera-
peutic partnership to achieve immune-mediated systemic tumor
control [88]. In preclinical models, tumor irradiation induces
Fas upregulation by tumor cells, thereby enhancing Fas-dependent
CTL killing [89], and the effectiveness of cancer vaccines [87,
90, 91]. This was often accompanied by important tumor inﬂux
by CD8+ and/or abscopal effect [90]. Similarly, upregulation of
MHC class I molecules by tumor cells following irradiation
enhance the anti-tumor effect of adoptive cell therapy (ACT)
[92, 93]. Moreover, combining mAbs targeting important
immune checkpoints (CD137, CD40, PD-1, CTLA-4) with tumor
irradiation has shown promising synergistic activity [94–96]. In
humans, localized radiotherapy combined with immunothera-
peutic interventions has been shown to increase tumor-speciﬁc
T-cell number, and encouraging clinical results have been
reported in patients with hepatocellular carcinoma or prostate
cancer [97–99]. Clinical trials combining radiotherapy with imi-
quimod (a TLR7 agonist) (NCT01421017), fresolimumab (a mAb
that neutralizes TGF-β) (NCT01401062) or ipilimumab (a mAb
directed against CTLA-4) (NCT01689974) are actually ongoing,
paving the way for the use of radiation as a partner for immuno-
therapy (Table 2).
combining chemotherapy with immunotherapy
Because most chemotherapeutic agents were regarded as immu-
nosuppressants, combinations between immunotherapy and
chemotherapy were long considered as incompatible. However,
the emergence of the concept of ICD (discussed above), the
observations that some chemotherapies such as cyclophospha-
mide and 5-ﬂuorouracil can eliminate regulatory immune cell
subsets (reviewed in [111, 112]) and some clinical trials results
showing that patients treated ﬁrst with immunotherapy, fol-
lowed by chemotherapy demonstrated better clinical outcomes
than patients that have received chemotherapy alone [113, 114],
have prompted scientists and physicians to reassess the potential
of combination therapies between chemotherapy and immuno-
therapy. Subsequent preclinical and clinical investigations have
revealed that chemotherapy could enhance the efﬁcacy of immuno-
therapy through various mechanisms (Table 3 and Figure 1).
Chemotherapy can not only improve anti-tumor effects of im-
munotherapy by overcoming parts of immunosuppression, but
also by enhancing cross-presentation of tumor antigens and by
supporting better penetration of immune cells in tumor core
(Table 3 and Figure 1).
combining targeted therapies with immunotherapy
small molecules. Among targeted therapies, number of tyrosine
kinase inhibitors (TKIs), proteasome inhibitors or mTOR
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Table 2. Non-exhaustive list of ongoing clinical trials investigating the effect of combination therapies (also reviewed in [100–110])
Therapeutic agent Cancer Clinical
phase
Combined with Reference
Imiquimod Breast cancer with skin metastases II Radiotherapy + cyclophosphamide NCT01421017
Fresolimumab Metastatic breast cancer I/II Radiotherapy NCT01401062
Ipilimumab Metastatic melanoma II Radiotherapy NCT01689974
Multipeptide cancer
vaccine
Advanced/mRCC III Sunitinib NCT01265901
Peptide-based vaccine Advanced stage HER2-overexpressing breast
cancer
I/II Adoptive T-cell therapy NCT00791037
Trastuzumab High-risk/metastatic HER-2/Neu-
overexpressing breast cancer with no
evidence of disease
II Cyclophosphamide, and an allogeneic GM-CSF-
secreting breast tumor vaccine
NCT00847171
Trastuzumab Metastatic breast cancer overexpressing
HER-2/NEU
II DC vaccine given with and vinorelbine NCT00266110
Trastuzumab HER2 positive breast cancer II Peptide-based vaccine NCT00343109
Nivolumab or
ipilimumab with
nivolumab
Resected stages IIIC/ IV melanoma I Vaccine combining multiple class I peptides and
montanide ISA 51VG
NCT01176474
Anti-PD-1 antibody
BMS-936558
Unresectable stages III/IV melanoma I Multiple class I peptides and montanide ISA 51
VG
NCT01176461
MPDL3280A Metastatic melanoma Ib Vemurafenib and cobimetinib NCT01656642
Ipilimumab Cervical carcinoma I Combined with cisplatin and radiation therapy NCT01711515
Ipilimumab CrC lymphoma melanoma I/II Combined with radiation therapy NCT01769222
Ipilimumab Head and neck cancer I Combined with cetuximab and radiation therapy NCT01860430
Ipilimumab Head and neck cancer I Combined with cetuximab and radiation therapy NCT01935921
Ipilimumab Hodgkin’s lymphoma I Combined with brentuximab vedotin NCT01896999
Ipilimumab Leukemia lymphoma n.a. Combined with lenalidomide NCT01919619
Ipilimumab Lymphoma I Combined with rituximab NCT01729806
Ipilimumab Melanoma n.a. Followed by lymphodepletion, TIL infusion
and IL-2
NCT01701674
Ipilimumab Melanoma 0 Combined with radioembolization NCT01730157
Ipilimumab Melanoma I Combined with SrS or wBrT NCT01703507
Ipilimumab Melanoma I Combined with dabrafenib ± trametinib NCT01767454
Ipilimumab Melanoma I Combined with Ny-eSO-1-targeting
vaccine ±montanide
NCT01810016
Ipilimumab Melanoma I Combined with BCG NCT01838200
Ipilimumab Melanoma I/II As single agent or combined with oncolytic
virotherapy
NCT01740297
Ipilimumab Melanoma II Combined with cyclophosphamide NCT01740401
Ipilimumab Melanoma II As single agent or combined with IFNα-2b NCT01708941
Ipilimumab Melanoma II Combined with nivolumab NCT01783938
Ipilimumab Melanoma II Combined with paclitaxel NCT01827111
Ipilimumab Melanoma III Combined with nivolumab NCT01844505
Ipilimumab Melanoma III Combined with lambrolizumab NCT01866319
Ipilimumab Melanoma Iv Combined with high-dose IL-2 NCT01856023
Ipilimumab NSCLC I Combined with carboplatin, cisplatin and
paclitaxel
NCT01820754
Ipilimumab Pancreatic cancer II As single agent or combined with a GM-CSF-
secreting vaccine
NCT01896869
Ipilimumab Prostate cancer I Combined with sipuleucel-T NCT01832870
Ipilimumab Prostate cancer II After sipuleucel-T treatment NCT01804465
Ipilimumab Advanced solid tumors I Combined with imatinib NCT01738139
Ipilimumab Advanced solid tumors I Combined with lirilumab NCT01750580
Ipilimumab Advanced solid tumors I Combined with lenalidomide NCT01750983
Ipilimumab Advanced solid tumors I/II Combined with nivolumab NCT01928394
Lambrolizumab Melanoma II Combined with ipilimumab NCT01866319
Lambrolizumab Advanced solid tumors II/III As single agent or combined with conventional
chemotherapy
NCT01840579
Lirilumab Advanced solid tumors I Combined with nivolumab NCT01714739
Continued
Volume 26 | No. 9 | September 2015 doi:10.1093/annonc/mdv209 | 
Annals of Oncology reviews
inhibitors have been shown to inﬂuence immune response
against cancer cells, mostly by affecting T-cell or DC functions
[133–139], but also by depleting Tregs or myeloid derived
suppressor cells (MDSCs) as discussed above [140–142]. Thus, a
randomized phase III clinical trial is presently testing IMA901, a
multipeptide cancer vaccine (preceded by a single low dose of
cyclophosphamide), in combination with sunitinib in ﬁrst-line
metastatic renal cell carcinoma (mRCC; NCT01265901). This
constitutes one of the examples of this new strategy of chemo-
immunotherapy combining targeted therapy, immunotherapy
and immunogenic chemotherapy schedule. TKIs may disrupt
signal transducer and activator of transcription (STAT) signaling
pathways, thus potentially decreasing immunosuppression by
Tregs, MDSCs or DCs, making combinations with mAbs
blocking immune checkpoints also quite attractive [115,143,144].
STAT activation can also control the expression of several
immunosuppressive molecules (like PD-L1), providing further
rationale for combinations [145]. Numerous clinical trials are
actually testing anti-PD-1/PD-L1 mAbs with TKIs, especially in
mRCC patients, with encouraging preliminary results [146]. Of
note, emerging data demonstrate that the normalization of
tumor neovasculature by anti-angiogenic agents could improve
endogenous and vaccination-induced anti-tumor immune
responses [147–149].
tumor-targeting mAbs. Contribution of the immune response,
especially through antibody-dependent-cellular cytotoxicity, has
been demonstrated for the clinical efﬁcacy of therapeutic mAbs,
like rituximab [150], cetuximab [151] and trastuzumab [152].
Preclinical studies also have shown that trastuzumab is able to
stimulate adaptative anti-tumor immunity [153, 154] and that
combination of trastuzumab with anti-PD-1 and anti-CD137
can synergize [154, 155]. Some of these studies also suggest that
the synergy between anthracyclines and trastuzumab could be
Table 2. Continued
Therapeutic agent Cancer Clinical
phase
Combined with Reference
Lirilumab Advanced solid tumors I Combined with ipilimumab NCT01750580
MeDI4736 Advanced solid tumors I Combined with tremelimumab NCT01975831
Nivolumab Melanoma II Combined with ipilimumab NCT01783938
Nivolumab Melanoma III Combined with ipilimumab NCT01927419
Nivolumab Melanoma III Combined with ipilimumab NCT01844505
Nivolumab NSCLC II Combined with azacitidine ± entinostat NCT01928576
Nivolumab Advanced solid tumors I Combined with lirilumab NCT01714739
Nivolumab Advanced solid tumors II As single agent or combined with
immunotherapy
NCT01968109
Nivolumab Advanced solid tumors I/II As single agent or combined with ipilimumab NCT01928394
Tremelimumab Hepatocellular carcinoma I Combined with rFa and TaCe NCT01853618
Tremelimumab Advanced solid tumors I Combined with MeDI4736 NCT01975831
Urelumab Non-Hodgkin’s lymphoma, chronic
lymphocytic leukemia
I Combined with rituximab NCT01775631
Table 3. Main mechanisms by which conventional anticancer therapies could synergize with immunotherapy
Step of the anti-tumor immune
response
Effects of conventional anti-tumor treatment
on immune system
Potential synergistic activity with
immunotherapy
References
Elimination of immunosuppressive
cells
• Elimination of Tregs
• Elimination of MDSCs
• Reduction of PD-1 ligand expression
Tumor vaccination, ACT [115]
[116, 117]
[118–121]
Delivery of tumor antigen • Upregulation of MHC class I
• Increased cross-presentation
Tumor vaccination, ACT [92, 93, 122]
[123]
Activation of antigen presenting
cells
• Maturation and activation of DCs Anti-CTLA-4, tumor vaccination [12, 124]
Cross-presentation of tumor antigen • ICD Tumor vaccination [15, 80]
T-cell penetration in tumor • Disruption of tumor stroma
• Upregulation of adhesion molecule on tumor blood
vessels
• Normalization of tumor vasculature
ACT [125]
[126]
[127]
T-cell cytotoxicity against tumor
cells
• Upregulation of Fas on tumor cell
• High dose lymphodepleting chemotherapy
• Upregulation of MPR by tumor cells
• Th1 cytokine production
• Increased CTL avidity
Anti PD-1/PD-L1, tumor vaccination,
ACT
[89]
[128] [129]
[125]
[130]
[131]
Generation of memory T cells • Promotion of long-term memory Tumor vaccination [132]
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explained in part by increased anti-tumor immune response
[154]. Combinatorial approaches of tumor vaccines with passive
immunotherapy have been developed in HER2-overexpressing
breast cancer. In metastatic breast cancer patients previously
treated with trastuzumab, association of HER2-based peptide
vaccine and trastuzumab resulted in boosting and prolongation
of T-cell response against HER2, with an estimated progression
free survival of 33% at 3 years [156]. Preliminary results on the
clinical efﬁcacy of this combination [157–160], and its superiority
compared with vaccination alone [157], have also been reported
by other groups. Ongoing clinical trials incorporating immu-
nization with trastuzumab, with or without chemotherapy, are
currently ongoing (NCT00791037, NCT00847171, NCT00266
110, NCT00343109) [161].
immune checkpoint inhibitors. Preclinical, but also recent
clinical evidences suggest that mAbs targeting inhibitory immune
checkpoints can be used in combination. Concurrent PD-1
blockade with mAb blocking CTLA-4, LAG3 or TIM-3 has
shown preclinical signs for anti-tumor synergy without signiﬁcant
toxicity [65, 162, 163]. A recent study tested the combination of
nivolumab (anti-PD-1 mAb) with ipilimumab (anti-CTLA-4
mAb) in patients with advanced melanoma, at a concomitant or
sequential schedule (ipilimumab followed by nivolumab). A total
of 53 patients received concurrent treatment. The objective–
response rate for all patients in the concurrent group was 40%,
and at the maximum doses that were associated with an
acceptable level of severe adverse events (nivolumab at 1 mg/kg
and ipilimumab at 3 mg/kg) 53% of patients had an objective
response, all with tumor reduction of 80% or more. However,
grade 3 or 4 adverse events occurred in over half of the patients
but were generally reversible [55]. Checkpoint blockade has also
been combined with standard doses and regimens of cytotoxic
chemotherapy. Signs of potential efﬁcacy have been reported
with a combination of ipilimumab with sequential chemotherapy
in non-small cell lung cancer (NSCLC) patients [164], or in
metastatic melanoma [165]. A recent clinical study conducted in 30
metastatic breast cancer patients showed that the combination of
the immune checkpoint modulator IMP321 (recombinant soluble
LAG3/Ig fusion), preceded by standard dose weekly paclitaxel is
feasible, and is followed by objective response rates of 50%, and
immune activation of NK cells, as well as durable effector memory
CD8+ T-cell responses [166]. Moreover, synergy of anti-CTLA-4
associated with chemotherapy and radiotherapy has recently been
reported [167], and the combination of mAbs blocking PD-1/PD-
L1 with therapeutic vaccines or targeted anticancer agents (BRAF
inhibitor vemurafenib) is actually being explored in melanoma
(NCT01176474 and NCT01176461) and advanced metastatic
cancer patients (NCT01656642), respectively (Table 2).
conclusions
For immunologists, it has become clear that immunotherapeutic
strategies should engage multiple effector mechanisms to overcome
the immunosuppressive mechanisms of cancer. For patients
with metastatic cancer or larger burden of disease, a single
therapeutic agent is unlikely to be effective, and immunotherapy
should be combined with conventional cancer treatments, with
IL-2
IL-15
IL-21
PD-L1
Anti-PD-1
Anti-CTLA4
CTLA4
Fas
CD8 T cell
Tumor bed
Checkpoint inhibitor 
blockade
Cytokines
Sensitization to T cell lysis
Radiotherapy
5-Fluorouracil
Dacarbazine
Induction of immunogenic 
tumor cell death
Regulatory T cell
Myeloid derived 
suppressor cell
Elimination of 
immunosuppressive cells
Tumor cell Dendritic cell
Radiotherapy
Anthracyclines
Oxaliplatin
Cyclophosphamide
5-Fluorouracil
Gemcitabine
Figure 1. Molecular bases for the rationale to combine immunotherapy with anticancer agents. Conventional chemotherapeutic agents can (1) induce an
immunogenic form of tumor cell death, (2) eliminate immunosuppressive cells and (3) sensitize tumor cells to immune effector cells. Immunostimulatory
cytokines and checkpoint inhibitor blockers promote CD8 T-cell activation and prevent their subsequent dysfunction in the tumor microenvironment.
Combination therapies thus not only target tumor cells, but also enhance CD8 T-cell activation, ultimately resulting in enhanced anticancer effects.
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the aim of not only to reduce tumor load, but also to abrogate
immune tolerance and to enhance anticancer immune responses
(Table 3 and Figure 1). This opens a ﬁeld for fundamental and
clinical research to better develop the concept of chemoimmu-
notherapy, especially to design the optimal choice, schedule and
dose of therapeutic associations. As the success of these combined
approaches may rely on the crosstalk between cancer cells, tumor
stroma and the patient’s immune system, three major considera-
tions appear crucial for implementation of chemoimmunother-
apy efﬁcient combinations. First, cancer-bearing patients who
may beneﬁt from such combinations must be properly selected
using appropriate biomarkers, which underscores the crucial
need for predictive biomarkers that can be introduced in the clin-
ical routine. Second, the optimal choice of combinations along
with the schedule and dosage of administration of each compo-
nent of the chemoimmunotherapy treatment remain to be deter-
mined, which highlights the need to develop clear immune
biological and clinical parameters that allow for rapid go/no-go
decisions. Finally, it is important to keep in mind that cancer
patients are often heavily co-medicated with a number of drugs
for symptom management as well as over-the-counter products
and supplements, which can also affect the immune system.
Future research and clinical trials that will rationally sequence
immunomodulators, cancer vaccines and conventional treat-
ments of cancer will beneﬁt from taking into account these im-
portant aspects.
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